ResMed (NYSE:RMD) said today that it inked a deal to acquire Propeller Health and its digital medicine platform for $225 million in cash. Propeller Health, which sells small sensors that attach to inhalers and track medication use, will operate as a standalone business under ResMed’s respiratory care portfolio. ResMed reported that Propeller’s products for people […]
Respiratory
Pulmatrix raises $3m in offering
Pulmatrix (NSDQ:PULM) said this week that it inked a deal with an institutional investor to sell 9,375,000 shares of common stock at 32¢ apiece. The Lexington, Mass.-based company expects to reel in $3 million in total gross proceeds from the offering. Pulmatrix also agreed to issue unregistered warrants to the same investor in a private placement […]
Propeller Health touts link between air pollution, rescue inhaler use in nationwide asthma study
Propeller Health today touted results from a nationwide study that indicated a direct association between daily air pollution and rescue inhaler use. Results from the study, which spanned five years and involved more than 2,800 individuals with asthma, were published in the Proceedings of the National Academy of Sciences, the Madison, Wisc.-based company said. Researchers in […]
FDA approves over-the-counter Primatene Mist inhaler
The FDA this week approved Amphastar Pharmaceuticals‘ (NSDQ:AMPH) over-the-counter Primatene Mist inhaler for the temporary relief of mild symptoms of intermittent asthma. The original version of Amphastar’s Primatene Mist device was taken off the market in 2011 because it contained chlorofluorocarbon propellants – a chemical compound that is linked to depletion of the Earth’s ozone […]
Pari Pharma lands FDA nod for Lamira nebulizer
Pari Pharma said this week that its Lamira nebulizer won approval from the FDA to deliver Insmed’s Arikayce amikacin liposome inhalation suspension for the treatment of MAC lung disease. The company’s Lamira drug-device combination product is intended to be used as part of a combination antibacterial drug regimen for adult patients with limited or no […]
AstraZeneca touts long-term safety, efficacy data for asthma biologic
AstraZeneca (NYSE:AZN) today touted results from a Phase III extension trial evaluating the long-term safety and efficacy of benralizumab as an add-on maintenance therapy for patients with severe eosinophilic asthma. Benralizumab, or Fasenra, is approved as an add-on maintenance treatment for severe eosinophilic asthma in an array of countries, including the U.S., the E.U., and Japan. […]
Kaleo partners with Walgreens to offer epinephrine auto-injector
Kaleo said this week that its epinephrine auto-injector, Auvi-Q, is available at Walgreens locations across the U.S. The partnership comes as the country is dealing with a shortage of the emergency allergy therapies – a number of epinephrine auto-injector manufacturers have reported supply issues to the FDA. In August, Kaleo confirmed that despite ongoing manufacturing delays […]
In midst of Epipen shortage, Kaleo confirms ‘sufficient supply’ of Auvi-Q auto-injectors
Kaleo said today that despite ongoing manufacturing delays reported by epinephrine auto-injector manufacturers, Kaleo’s Auvi-Q device is available via prescription and that the privately-held company has ‘sufficient supply to meet any anticipated demand.’ Kaleo’s epinephrine auto-injector features voice instructions that guide users through the drug-delivery process and an auto-retractable needle system, according to the company. […]
Adherium launches over-the-counter inhaler sensor in US
Adherium (ASK:ADR) today launched over-the-counter sales of its Hailie digital inhaler add-on in the U.S. The sensor is designed to integrate directly with prescription inhaler medications, sending adherence reminders and relevant data to a user’s smartphone to assist in managing chronic respiratory conditions like asthma and COPD. “We’re extremely excited to announce the availability of the […]
Acorda’s CEO on failure, perseverance and the profound risks of drug development
Dr. Ron Cohen isn’t easily deterred. The physician-turned-executive has spent decades in the biotech industry and weathered a number of setbacks – he learned in his early years at the now-defunct Advanced Tissue Sciences that to succeed, he needed resilience. “I learned that it took hundreds of millions of dollars if not billions to develop […]